AVANT Immunotherapeutics, Inc. Will Release Its Fourth Quarter and Fiscal 2001 Financial Results Before the Market Opens On February 26, 2002
NEEDHAM, Mass.--(BW HealthWire)--Feb. 19, 2002--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - news) will release its fourth quarter and fiscal 2001 financial results before the market opens on February 26, 2002.
AVANT Imuunotherapeutics, Inc. CEO, Una S. Ryan, and CFO, Avery W. Catlin, will host a conference call at 11:00 EDT on February 27, 2002. To access the live call, dial 800-360-9865 (within the United States) or 973-694-6836 (outside the United States). A replay will be available approximately two hours after the call through March 6, 2002. To access the replay, dial 800-428-6051 (within the United States) or 973-709-2089 (outside the United States). The passcode I.D. # is 232692. The call will also be broadcast via the company's website www.avantimmune.com.
AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a broad portfolio of vaccines against viral and bacterial diseases, including single-dose oral vaccines aimed at protecting travelers from cholera, typhoid fever and other illnesses. AVANT is also developing compounds with the potential to inhibit harmful complement activation that occurs in response to surgery. In addition, the company is conducting clinical studies of a proprietary vaccine candidate for cholesterol management. AVANT further leverages the value of its technology portfolio through corporate partnerships. Current collaborations encompass the development of an oral human rotavirus vaccine, vaccines to combat threats of biological warfare, and vaccines addressed to human food safety and animal health.
--------------------------------------------------------------------------------
Contact:
Una S. Ryan, Ph.D.
President and CEO
AVANT Immunotherapeutics, Inc.
(781) 433-0771
or
Avery W. Catlin
Chief Financial Officer
AVANT Immunotherapeutics, Inc.
(781) 433-0771
info@avantimmune.com
or
For Media:
Joan Kureczka/Jesse Fisher
Kureczka/Martin Associates
(415) 821-2413
jkureczka@aol.com |
